ムコ多糖症治療の世界市場レポート 2025年

ムコ多糖症治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.9％で35億1,000万米ドルに成長します。予測期間の成長は、遺伝子編集の進歩、規制の変更と支援、患者アクセスの取り組み、新たな治療様式、精密医療アプローチに起因すると考えられます。予測期間における世界の動向には、介護者支援プログラム、症状管理への注力、教育・訓練イニシアティブ、世界アクセスの拡大、バイオマーカー開発の進展などが含まれます。

さまざまな形態のムコ多糖症の有病率の上昇は、今後のムコ多糖症治療市場の成長を後押しすると予想されます。ムコ多糖は複合糖質の一種であり、その分解に必要な特定の酵素が存在しないために体組織に蓄積します。ムコ多糖症（MPS）治療は、様々な治療アプローチを通じて、グリコサミノグリカン（GAG）の蓄積を抑え、症状を管理し、合併症を予防することで、疾患の進行を遅らせるのに役立ちます。例えば、2024年7月、フランスを拠点とするオープンアクセスの査読付き医学雑誌であるOrphanet Journal of Rare Diseasesは、ムコ多糖症IVa（MPS IVa）の罹患率は出生数201,000人に1人と推定されると報告しているが、この数字は集団によって大きく異なると考えられています。同様に、ムコ多糖症VI（MPS VI）の出生時有病率は、集団によって異なるが、43,261人に1人から1,505,160人に1人と推定されています。その結果、さまざまな形態のムコ多糖症の有病率の増加がムコ多糖症治療市場を牽引すると予想されます。

ヘルスケア支出の増加がムコ多糖症治療市場の拡大に寄与しています。ヘルスケア支出とは、特定の地域、国、組織内のヘルスケア部門に捧げられる総財源を指します。ヘルスケア支出の増加はムコ多糖症（MPS）治療に向けられ、専門的治療、調査、医療インフラへのアクセスを改善することで、この稀な遺伝性疾患に罹患した人々の管理と転帰を向上させることを目指しています。例えば、2024年7月、米国を拠点とする医師と医学生の専門組織である米国医師会は、2022年の米国の医療支出が4.1％増加し、4兆5,000億米ドル、国民一人当たり1万3,493米ドルに達したと報告しました。したがって、ヘルスケア支出の増加がムコ多糖症治療市場の今後の成長を牽引することになります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ムコ多糖症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のムコ多糖症治療市場：成長率分析
• 世界のムコ多糖症治療市場の実績：規模と成長, 2019-2024
• 世界のムコ多糖症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界ムコ多糖症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のムコ多糖症治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 酵素補充療法
• 幹細胞療法
• 世界のムコ多糖症治療市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ムコ多糖症-I
• ムコ多糖症-II
• ムコ多糖症IV
• ムコ多糖症-VI
• その他の病気
• 世界のムコ多糖症治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内
• 脳室内
• 世界のムコ多糖症治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• その他のエンドユーザー
• 世界のムコ多糖症治療市場酵素補充療法の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• イデュルスルファーゼ（エラプレーゼ）
• ラロニダーゼ（アルデュラザイム）
• ベラグルセラーゼアルファ（Vpriv）
• ガルスルファーゼ（ナグラザイム）
• 世界のムコ多糖症治療市場幹細胞療法の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 造血幹細胞移植（HSCT）
• 臍帯血移植
• 遺伝子治療のアプローチ

第7章 地域別・国別分析

• 世界のムコ多糖症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のムコ多糖症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ムコ多糖症治療市場：競合情勢
• ムコ多糖症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• BioMarin Pharmaceuticals Inc.
• Mallinckrodt Pharmaceuticals
• Green Cross Corporation
• Sarepta Therapeutics Inc.
• Esteve SA
• JCR Pharmaceuticals Co. Ltd.
• Ultragenyx Pharmaceutical Inc.
• RegenxBio Inc.
• Sangamo Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ムコ多糖症治療市場2029：新たな機会を提供する国
• ムコ多糖症治療市場2029：新たな機会を提供するセグメント
• ムコ多糖症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

The treatment of Mucopolysaccharidosis (MPS) involves addressing hereditary illnesses characterized by the body's inability to break down glycosaminoglycan (long sugar chains) due to the deficiency or malfunction of specific enzymes, often lysosomal enzymes.

Two primary types of treatments for mucopolysaccharidosis are enzyme replacement therapy and stem cell therapy. Enzyme replacement therapy is a medical intervention designed for patients with chronic diseases resulting from enzyme deficiency or dysfunction. This approach involves providing replacement enzymes to individuals affected by various forms of mucopolysaccharidosis, including types I, II, IV, VI, and others. These replacement enzymes are administered through intravenous and intracerebroventricular routes of administration. The therapy is implemented in diverse healthcare settings, including hospitals, specialty clinics, and other medical facilities.

The mucopolysaccharidosis treatment market research report is one of a series of new reports from The Business Research Company that provides mucopolysaccharidosis treatment market statistics, including mucopolysaccharidosis treatment industry global market size, regional shares, competitors with a mucopolysaccharidosis treatment market share, detailed mucopolysaccharidosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the mucopolysaccharidosis treatment industry. This mucopolysaccharidosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mucopolysaccharidosis treatment market size has grown strongly in recent years. It will grow from $2.4 billion in 2024 to $2.59 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to enzyme replacement therapy (ERT), improved diagnostic tools, advocacy and awareness, gene therapy development, and healthcare infrastructure development

The mucopolysaccharidosis treatment market size is expected to see strong growth in the next few years. It will grow to $3.51 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to advancements in gene editing, regulatory changes and support, patient access initiatives, emerging therapeutic modalities, and precision medicine approaches. Major trends in the forecast period include caregiver support programs, focus on symptom management, education and training initiatives, expanded global access, and advances in biomarker development.

The rising prevalence of various forms of mucopolysaccharidosis is anticipated to boost the growth of the mucopolysaccharidosis treatment market in the future. Mucopolysaccharide is a type of complex carbohydrate that accumulates in body tissues due to the absence of the specific enzyme required for its breakdown. Mucopolysaccharidosis (MPS) therapy helps slow disease progression by reducing glycosaminoglycan (GAG) accumulation, managing symptoms, and preventing complications through various treatment approaches. For example, in July 2024, the Orphanet Journal of Rare Diseases, a peer-reviewed open-access medical journal based in France, reported that the incidence of mucopolysaccharidosis IVa (MPS IVa) is estimated at approximately 1 in 201,000 live births, although this number is believed to vary significantly across populations. Similarly, the birth prevalence of mucopolysaccharidosis VI (MPS VI) is estimated to range from 1 in 43,261 to 1 in 1,505,160, depending on the population. As a result, the increasing prevalence of different forms of mucopolysaccharidosis is expected to drive the mucopolysaccharidosis treatment market.

The rise in healthcare spending is contributing to the expansion of the mucopolysaccharidosis treatment market. Healthcare spending refers to the total financial resources dedicated to the healthcare sector within a particular region, country, or organization. The increase in healthcare spending is being directed toward mucopolysaccharidosis (MPS) treatment, aiming to improve access to specialized therapies, research, and medical infrastructure, thus enhancing the management and outcomes for individuals affected by this rare genetic disorder. For example, in July 2024, the American Medical Association, a U.S.-based professional organization of physicians and medical students, reported that health spending in the United States grew by 4.1% in 2022, reaching $4.5 trillion, or $13,493 per capita. Therefore, the rise in healthcare spending is driving the growth of the mucopolysaccharidosis treatment market moving forward.

Product innovation is an emerging trend gaining traction in the mucopolysaccharidosis treatment market. Leading companies in this market are concentrating on developing new products to maintain their competitive edge. For example, in September 2022, Ultragenyx Pharmaceutical Inc., a U.S.-based biopharmaceutical company, launched Vestronidase alfa (Mepsevii) in Japan for the treatment of Mucopolysaccharidosis Type VII (MPS VII or Sly Syndrome). This enzyme replacement therapy is designed to address the enzyme deficiency in MPS VII, helping break down glycosaminoglycans (GAGs) and reducing their buildup in tissues and organs. Mepsevii improves patients' mobility and respiratory function, offering a transformative treatment for individuals with this rare and progressive disorder. Its approval marks a significant advancement in providing essential care for rare disease patients in Japan.

Major players in the mucopolysaccharidosis treatment market are directing their focus towards cell therapies as a promising avenue for addressing rare genetic disorders. A case in point is ISP-001, developed by Immusoft, a US-based biotechnology company. ISP-001 represents a pioneering approach utilizing cell therapy to administer gene-encoded medicine, targeting the root cause of Mucopolysaccharidosis I (MPS I). In September 2022, Immusoft achieved a significant milestone with the FDA clearance of its Investigational New Drug (IND) application for ISP-001, marking a groundbreaking advancement in engineered B cell therapy for MPS I treatment.

In January 2024, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, acquired Orchard Therapeutics for an undisclosed sum. This acquisition is notable as it merges Kyowa Kirin's extensive experience in biopharmaceuticals with Orchard's innovative gene therapy platform, aimed at providing transformative treatments for patients with severe genetic disorders. Orchard Therapeutics, a UK-based biotech company, specializes in treatments for mucopolysaccharidosis, further enhancing the capabilities of both companies in addressing rare genetic diseases.

Major companies operating in the mucopolysaccharidosis treatment market include Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., BioMarin Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Green Cross Corporation, Sarepta Therapeutics Inc., Esteve SA, JCR Pharmaceuticals Co. Ltd., Ultragenyx Pharmaceutical Inc., RegenxBio Inc., Sangamo Therapeutics Inc., Audentes Therapeutics Inc., Eidos Therapeutics Inc., Neurogene Inc., Immusoft Corporation, Bioasis Technologies Inc., Paradigm Biopharmaceuticals Ltd., Rimedion Inc., Eloxx Pharmaceuticals Inc., iBio Inc., Abeona Therapeutics Inc.

North America was the largest region in the mucopolysaccharidosis treatment market in 2024. The regions covered in the mucopolysaccharidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the mucopolysaccharidosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mucopolysaccharides treatment market includes revenues earned by entities by providing medication services such as enzyme replacement therapy, stem cell transplantation, gene therapy, substrate reduction therapy, and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Mucopolysaccharidosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on mucopolysaccharidosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for mucopolysaccharidosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mucopolysaccharidosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Enzyme Replacement Therapy; Stem Cell Therapy
• 2) By Disease: Mucopolysaccharidosis- I; Mucopolysaccharidosis- II; Mucopolysaccharidosis-IV; Mucopolysaccharidosis-VI; Other Diseases
• 3) By Route Of Administration: Intravenous; Intracerebroventricular
• 4) By End-User: Hospitals; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Enzyme Replacement Therapy: Idursulfase (Elaprase); Laronidase (Aldurazyme); Velaglucerase Alfa (Vpriv); Galsulfase (Naglazyme)
• 2) By Stem Cell Therapy: Hematopoietic Stem Cell Transplantation (HSCT); Umbilical Cord Blood Transplantation; Gene Therapy Approaches
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Mucopolysaccharidosis Treatment Market Characteristics

3. Mucopolysaccharidosis Treatment Market Trends And Strategies

4. Mucopolysaccharidosis Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Mucopolysaccharidosis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Mucopolysaccharidosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Mucopolysaccharidosis Treatment Market Growth Rate Analysis
• 5.4. Global Mucopolysaccharidosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Mucopolysaccharidosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Mucopolysaccharidosis Treatment Total Addressable Market (TAM)

6. Mucopolysaccharidosis Treatment Market Segmentation

• 6.1. Global Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme Replacement Therapy
• Stem Cell Therapy
• 6.2. Global Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mucopolysaccharidosis- I
• Mucopolysaccharidosis- II
• Mucopolysaccharidosis-IV
• Mucopolysaccharidosis-VI
• Other Diseases
• 6.3. Global Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Intracerebroventricular
• 6.4. Global Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Other End-Users
• 6.5. Global Mucopolysaccharidosis Treatment Market, Sub-Segmentation Of Enzyme Replacement Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Idursulfase (Elaprase)
• Laronidase (Aldurazyme)
• Velaglucerase Alfa (Vpriv)
• Galsulfase (Naglazyme)
• 6.6. Global Mucopolysaccharidosis Treatment Market, Sub-Segmentation Of Stem Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hematopoietic Stem Cell Transplantation (HSCT)
• Umbilical Cord Blood Transplantation
• Gene Therapy Approaches

7. Mucopolysaccharidosis Treatment Market Regional And Country Analysis

• 7.1. Global Mucopolysaccharidosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Mucopolysaccharidosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Mucopolysaccharidosis Treatment Market

• 8.1. Asia-Pacific Mucopolysaccharidosis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Mucopolysaccharidosis Treatment Market

• 9.1. China Mucopolysaccharidosis Treatment Market Overview
• 9.2. China Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Mucopolysaccharidosis Treatment Market

• 10.1. India Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Mucopolysaccharidosis Treatment Market

• 11.1. Japan Mucopolysaccharidosis Treatment Market Overview
• 11.2. Japan Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Mucopolysaccharidosis Treatment Market

• 12.1. Australia Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Mucopolysaccharidosis Treatment Market

• 13.1. Indonesia Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Mucopolysaccharidosis Treatment Market

• 14.1. South Korea Mucopolysaccharidosis Treatment Market Overview
• 14.2. South Korea Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Mucopolysaccharidosis Treatment Market

• 15.1. Western Europe Mucopolysaccharidosis Treatment Market Overview
• 15.2. Western Europe Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Mucopolysaccharidosis Treatment Market

• 16.1. UK Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Mucopolysaccharidosis Treatment Market

• 17.1. Germany Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Mucopolysaccharidosis Treatment Market

• 18.1. France Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Mucopolysaccharidosis Treatment Market

• 19.1. Italy Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Mucopolysaccharidosis Treatment Market

• 20.1. Spain Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Mucopolysaccharidosis Treatment Market

• 21.1. Eastern Europe Mucopolysaccharidosis Treatment Market Overview
• 21.2. Eastern Europe Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Mucopolysaccharidosis Treatment Market

• 22.1. Russia Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Mucopolysaccharidosis Treatment Market

• 23.1. North America Mucopolysaccharidosis Treatment Market Overview
• 23.2. North America Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Mucopolysaccharidosis Treatment Market

• 24.1. USA Mucopolysaccharidosis Treatment Market Overview
• 24.2. USA Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Mucopolysaccharidosis Treatment Market

• 25.1. Canada Mucopolysaccharidosis Treatment Market Overview
• 25.2. Canada Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Mucopolysaccharidosis Treatment Market

• 26.1. South America Mucopolysaccharidosis Treatment Market Overview
• 26.2. South America Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Mucopolysaccharidosis Treatment Market

• 27.1. Brazil Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Mucopolysaccharidosis Treatment Market

• 28.1. Middle East Mucopolysaccharidosis Treatment Market Overview
• 28.2. Middle East Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Mucopolysaccharidosis Treatment Market

• 29.1. Africa Mucopolysaccharidosis Treatment Market Overview
• 29.2. Africa Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Mucopolysaccharidosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Mucopolysaccharidosis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Mucopolysaccharidosis Treatment Market Competitive Landscape
• 30.2. Mucopolysaccharidosis Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Mucopolysaccharidosis Treatment Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. GlaxoSmithKline plc
• 31.5. Takeda Pharmaceutical Co. Ltd.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. BioMarin Pharmaceuticals Inc.
• 31.8. Mallinckrodt Pharmaceuticals
• 31.9. Green Cross Corporation
• 31.10. Sarepta Therapeutics Inc.
• 31.11. Esteve SA
• 31.12. JCR Pharmaceuticals Co. Ltd.
• 31.13. Ultragenyx Pharmaceutical Inc.
• 31.14. RegenxBio Inc.
• 31.15. Sangamo Therapeutics Inc.

32. Global Mucopolysaccharidosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Mucopolysaccharidosis Treatment Market

34. Recent Developments In The Mucopolysaccharidosis Treatment Market

35. Mucopolysaccharidosis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Mucopolysaccharidosis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Mucopolysaccharidosis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Mucopolysaccharidosis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer